Immix Biopharma (IMMX) Return on Capital Employed (2022 - 2026)
Immix Biopharma (IMMX) reported Return on Capital Employed of 40.18% for Q1 2026, up 13953.0% on a YoY basis from N/an in Q1 2025, and up 29.78% sequentially from 57.22% in Q4 2025.
Immix Biopharma (IMMX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 5 years of Return on Capital Employed data on file, last reported at 40.18% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 13953.0% year-over-year to 40.18%; the trailing twelve-month figure through Mar 2026 stood at 40.18% (up 13953.0% YoY), and the FY2025 full-year result was 55.7%, up 12215.0% from the prior year.
- Return on Capital Employed rose to 40.18% in Q1 2026, from 57.22% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 13.44% in Q1 2022 to a low of 343.22% in Q3 2025.
- A 5-year average of 107.14% and a median of 89.44% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 23380 bps in 2025 and soared 13953 bps in 2026, its largest moves.
- Tracing IMMX's Return on Capital Employed over 5 years: stood at 55.24% in 2022, then plunged by 67 bps to 92.35% in 2023, then sank by 60 bps to 147.64% in 2024, then surged by 61 bps to 57.22% in 2025, then gained by 30 bps to 40.18% in 2026.
- Business Quant data shows IMMX's Return on Capital Employed at 40.18% in Q1 2026, 57.22% in Q4 2025, and 343.22% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - | -40.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.18% |
| Dec 31, 2025 | -57.22% |
| Sep 30, 2025 | -343.22% |
| Jun 30, 2025 | -306.72% |
| Mar 31, 2025 | -179.71% |
| Dec 31, 2024 | -147.64% |
| Sep 30, 2024 | -112.92% |
| Jun 30, 2024 | -72.92% |
| Mar 31, 2024 | -89.44% |
| Dec 31, 2023 | -92.35% |
| Sep 30, 2023 | -89.90% |
| Jun 30, 2023 | -96.47% |
| Mar 31, 2023 | -74.76% |
| Dec 31, 2022 | -55.24% |
| Sep 30, 2022 | -28.55% |
| Jun 30, 2022 | -20.66% |
| Mar 31, 2022 | -13.44% |